Abstract
1882O RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have